What is the history of POEMS syndrome?

POEMS syndrome was first formally recognized as a distinct clinical entity in 1980 by Dr. Yoshihiro Bardwick, who coined the acronym to describe its five cardinal features: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes. While individual symptoms had been documented in medical literature as early as the 1950s, the synthesis of these findings into a unified syndrome represented a major milestone in understanding this rare plasma cell dyscrasia.

How was POEMS syndrome first identified?

Before the 1980s, patients presenting with the complex array of symptoms now known as POEMS syndrome were often misdiagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP) or other systemic autoimmune disorders. It was not until Japanese researchers, led by Dr. Bardwick, observed a consistent pattern of peripheral neuropathy occurring alongside specific organ and endocrine dysfunctions that the syndrome was clearly defined. The medical community initially struggled to connect these disparate symptoms, as the underlying cause—a rare underlying plasma cell disorder—was not well understood at the time.

How has our understanding of POEMS syndrome evolved?

The evolution of POEMS syndrome research has shifted from a purely descriptive approach to a molecular one. In the early years, clinicians focused on palliative management of symptoms. However, the discovery that the syndrome is driven by the overproduction of vascular endothelial growth factor (VEGF) revolutionized the field. Researchers now understand that POEMS syndrome is a paraneoplastic syndrome caused by an underlying clonal plasma cell disorder, which allows for more targeted therapeutic interventions rather than just symptom management.

What are the major milestones in treating POEMS syndrome?

Treatment for POEMS syndrome has transitioned from supportive care to aggressive, targeted therapies that address the underlying plasma cell clone. Historical milestones include:

• 1980s: Initial reliance on corticosteroids and symptomatic management with limited success.


• 1990s: Introduction of radiation therapy (localized) for patients with solitary bone lesions.


• 2000s: The adoption of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT), which significantly improved long-term outcomes.


• 2010s-Present: The emergence of novel agents, including immunomodulatory drugs (IMiDs) like lenalidomide, providing options for patients who cannot tolerate aggressive transplantation.

How has modern technology changed the landscape for patients?

Modern advancements in hematology and imaging have drastically reduced the time to diagnosis for POEMS syndrome. Previously, patients often spent years in diagnostic "limbo." Today, the use of serum protein electrophoresis (SPEP), immunofixation, and the measurement of serum VEGF levels allows for a much faster and more accurate diagnosis. Furthermore, the 59 members of the DiseaseMaps.org community reflect a growing trend of patients using digital platforms to share their diagnostic journeys, which helps researchers identify patterns and advocate for earlier screening in neurology and hematology clinics.

Next steps

• Consult a hematologist-oncologist who has specific clinical experience with plasma cell dyscrasias.


• Request a measurement of serum VEGF levels if POEMS syndrome is suspected, as this is a key diagnostic biomarker.


• Connect with the POEMS syndrome patient community at DiseaseMaps.org to share experiences and find peer support.


• Coordinate care between your neurologist and hematologist to ensure that both the neuropathy and the underlying plasma cell clone are being addressed.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): POEMS syndrome overview.


• Orphanet: Rare disease database entry for POEMS syndrome.


• PubMed: Bardwick PA, et al. "Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome." Medicine (Baltimore), 1980.


• OMIM (Online Mendelian Inheritance in Man): Clinical features and molecular basis of plasma cell dyscrasias.